GP KFPs / SAQs · mens-health
Erectile dysfunction — KFP-style written assessment
KFP-style staged scenarios on erectile dysfunction: the cardiovascular-lens first consultation, PDE5 inhibitor counselling with trial numbers and contraindications, testosterone in the non-responder, second-line escalation with injections and vacuum devices, and psychosexual therapy for psychogenic disease.
On this page
Study tools
Target exams
RACGP KFPRACGP AKTMRCGP AKT
Prompt
ED: a symptom that talks about arteries — assessing honestly, prescribing safely, escalating deliberately
KFP 1 (10 marks)
A 49-year-old solicitor attends after his partner insisted. Six months of gradual ED; morning erections still present most days but intercourse fails. Smokes 15/day, BMI 31, no regular doctor. His father had a bypass at 58.[6] [10]
- Outline your assessment, including why this presentation demands more than an ED prescription. (4) [6] [10]
- His bloods return: total cholesterol 6.8 mmol/L, HbA1c 5.9%, BP 148/92. How do these findings integrate? (3) [10] [1]
- He wants 'the blue tablet' immediately. What lifestyle prescriptions accompany it? (3) [8] [15]
Model answers
- Take the sexual history properly (onset, morning erections — preserved here, situational pattern), score IIEF-5, review medications and alcohol, screen depression, then assess cardiovascular risk formally. ED is a vascular warning sign: incident ED carried HR 1.25 (CI 1.02-1.53) for subsequent cardiovascular events, and prevalent or incident ED together HR 1.45 (CI 1.25-1.69); meta-analysis gives RR 1.62 for myocardial infarction, highest at younger ages — he is exactly that man. His father's premature bypass strengthens the case. [6] [10]
- The cluster (dyslipidaemia, borderline glycaemia, hypertension, obesity, smoking) is the same risk-factor bundle driving both his ED and future coronary events; MMAS showed impotence correlating directly with heart disease, hypertension and diabetes independent of age. Manage it as early vascular disease: formal absolute-risk calculation, lipid modification, BP treatment, smoking cessation — not just symptomatic therapy. [10] [1]
- Lifestyle change is evidence-based ED treatment, not an add-on: six randomised trials showed lifestyle interventions plus CV-risk pharmacotherapy improved IIEF-5 by weighted mean 2.66 points (CI 1.86-3.47). Smoking cessation specifically raised total IIEF within six months across age subgroups. Frame both as treatments for erections AND arteries, prescribed alongside sildenafil rather than instead of it. [8] [15]
References13ShowHide
- [1]Feldman HA, Goldstein I, Hatzichristou DG et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. The Journal of urology, 1994.PMID 8254833
- [2]Rosen RC, Riley A, Wagner G et al. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology, 1997.PMID 9187685
- [6]Thompson IM, Tangen CM, Goodman PJ et al. Erectile dysfunction and subsequent cardiovascular disease. JAMA, 2005.PMID 16414947
- [10]Vlachopoulos CV, Terentes-Printzios DG, Ioakeimidis NK et al. Prediction of cardiovascular events and all-cause mortality with erectile dysfunction: a systematic review and meta-analysis of cohort studies. Circulation. Cardiovascular quality and outcomes, 2013.PMID 23300267
- [8]Gupta BP, Murad MH, Clifton MM et al. The effect of lifestyle modification and cardiovascular risk factor reduction on erectile dysfunction: a systematic review and meta-analysis. Archives of internal medicine, 2011.PMID 21911624
- [15]Sahin MO, Sen V, Gunduz G et al. Effect of smoking cessation on sexual functions in men aged 30 to 60 years. International braz j urol : official journal of the Brazilian Society of Urology, 2020.PMID 32374127
- [3]Goldstein I, Lue TF, Padma-Nathan H et al. Oral sildenafil in the treatment of erectile dysfunction. Sildenafil Study Group. The New England journal of medicine, 1998.PMID 9580646
- [11]Yang M, Ni X, Sontag A et al. Nonresponders, partial responders, and complete responders to PDE5 inhibitors therapy according to IIEF criteria: validation of an anchor-based treatment responder classification. The journal of sexual medicine, 2013.PMID 24125113
- [12]Corona G, Rastrelli G, Morgentaler A et al. Meta-analysis of Results of Testosterone Therapy on Sexual Function Based on International Index of Erectile Function Scores. European urology, 2017.PMID 28434676
- [14]Duncan C, Omran GJ, Teh J et al. Erectile dysfunction: a global review of intracavernosal injectables. World journal of urology, 2019.PMID 30895359
- [18]Zhang F, Luo Z, Xue Q et al. Efficacy of vacuum erectile device in refractory erectile dysfunction: a systematic review and meta-analysis. International journal of impotence research, 2026.PMID 40542251
- [17]Cocci A, Capogrosso P, Minhas S et al. Penile prosthesis implantation: a systematic review of intraoperative and postoperative complications. International journal of impotence research, 2026.PMID 40514408
- [7]Melnik T, Soares BG, Nasello AG The effectiveness of psychological interventions for the treatment of erectile dysfunction: systematic review and meta-analysis, including comparisons to sildenafil treatment, intracavernosal injection, and vacuum devices. The journal of sexual medicine, 2008.PMID 18564156